July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Steven Kridel: Poster symposium at the end of the 2024 Program to Enhance Diversity in Cancer Research
Jul 29, 2024, 11:28

Steven Kridel: Poster symposium at the end of the 2024 Program to Enhance Diversity in Cancer Research

Ruben Mesa shared  a post by , Chair, Department of Cancer Biology at Wake Forest University School of Medicine, on LinkedIn:

“Outstanding program! Grateful to the participants and our super enthusiastic CRTEC team of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center!! ”

Quoting

“Today was the poster symposium to celebrate the end of the 2024 Program to Enhance Diversity in Cancer Research in the Department of Cancer Biology at Wake Forest University School of Medicine and the Atrium Health Wake Forest Baptist Comprehensive Cancer Center. Our scholars from Winston-Salem State University, North Carolina Agricultural and Technical State University, North Carolina State University, University of North Carolina at Pembroke, University of North Carolina at Chapel Hill and University of South Carolina presented posters on their summer research projects. It was great to meet the students family and friends while they showed off their work. This is one of the best days each summer and I look forward to being able to continue the program. This is just one step to enhance diversity in STEM. Thank you at all the faculty, students, and staff who helped mentor our summer scholars!”

Source: Ruben Mesa/LinkedIn and /LinkedIn

Ruben Mesa, MD, FACP, serves as the president and executive director of Atrium Health Levine Cancer Institute (LCI) and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. Additionally, he holds the position of vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine. He is an international expert in hematologic cancers, particularly myeloproliferative neoplasms (MPNs). Through his tireless efforts, Dr. Mesa continues to drive progress in the understanding and treatment of hematologic malignancies, offering hope to those affected by these complex diseases.